Trial · NCT04514458
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy | Assessed from the date of randomization to 30 days post-randomization | Observed in patient subjects only. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Patients on Beta Blockers | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on ACE Inhibitors | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on ARBs | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on ARNIs | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on MRAs | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on SGLT2 Inhibitors | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of One-year All-cause Mortality | Assessed from the date of randomization to the date of death from any cause, up to 365 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of 30-day Hospital Admission | Assessed from the date of randomization to the date of hospital admission, up to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of 30-day All-cause Emergency Department Visits | Assessed from the date of randomization to the date of ED/ER admission, up to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Total Six-month Healthcare Costs | Assessed from the date of randomization to 6 months post-randomization | The data necessary to analyze this outcome was unable to be released from the university analytics team, therefore we cannot report cost results. The Finance Administration at Yale did not grant approval for access to this data. The data was not collected and will not be accessed in the future. | ||
| SECONDARY | Percentage of Filled Prescriptions | Assessed 6 months post-randomization | Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained. | ||
| SECONDARY | Medication Dose of Any Prescribed Beta Blocker | Assessed at 6 months post-randomization | Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained. | ||
| SECONDARY | Medication Dose of Any Prescribed ACEi | Assessed at 6 months post-randomization | Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained. | ||
| SECONDARY | Medication Dose of Any Prescribed ARB | Assessed at 6 months post-randomization | Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained. | ||
| SECONDARY | Medication Dose of Any Prescribed ARNI | Assessed at 6 months post-randomization | Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained. | ||
| SECONDARY | Medication Dose of Any Prescribed MRA | Assessed at 6 months post-randomization | Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained. | ||
| SECONDARY | Medication Dose of Any Prescribed SGLT2 Inhibitor | Assessed at 6 months post-randomization | Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04514458/outcomes